The company plans to file an application with US regulators in the coming weeks
Moderna said on Monday that its experimental vaccine was 94.5% effective in preventing COVID-19, according to interim results from large clinical trials..
Moderna became the second drug manufacturer in the United States to report results that far exceeded expectations. Pfizer reported 90% effectiveness of its vaccine last week.
Following additional safety findings and regulatory validation, the two vaccines could be approved in the US as early as December. Up to 60 million doses are expected to be available this year.
More than 1 billion doses from these two manufacturers alone could be available in the country next year, more than 330 million people need..
Developed using a new technology known as messenger or messenger RNA (mRNA), both vaccines are powerful tools to fight the pandemic. At the moment, there are 54 million cases in the world and more than 1.3 million deaths from coronavirus..
The number of cases of infection with COVID-19 is growing rapidly. In the United States, record incidence rates are recorded, and a number of European countries were forced to re-introduce quarantine.
«We will have a vaccine to stop COVID-19», – said Moderna President Stephen Hoge in a telephone interview.
Moderna’s interim analysis was based on 95 infections among trial participants who received either a placebo or a vaccine. Of these, only five cases were in volunteers who received the vaccine, which is administered in two doses with an interval of 28 days. A total of 30,000 people participate in the tests, including those from risk groups.
Moderna expects that it will have enough security data to register in the US in the next week or so. The company expects to apply for emergency use in the coming weeks.
Moderna: Covid-19 vaccine has efficacy rate of 94.5%
Ahead of the opening of trading, the company’s shares rose 9.1 percent. The news of the Moderna vaccine also boosted European equities and Wall Street stock futures. S Index Futures&The P 500 is up 1.3 percent to near a new all-time high, while the pan-European STOXX 600 index hits late February highs.
Sources: Disagreements exist between Moderna and government experts